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EVENTS DURING ACUTE HIV INFECTlON
developed countries. The range 0' opportunistic illnesses is
significantly different, though, probably reflecting the





The acute antiretroviral syndrome, or 'seroconversion', is
usually but not always symptomatic. Symptoms vary from
minor 'flu-like' symptoms to severe illness requiring
hospitalisation. The infected person or his or her health
care practitioner often dismisses the symptoms, especially
in pressured, resource-poor environments like South Africa.
Prolonged persistence or severity of the seroconversion
illness is an independent risk factor for more rapid
progression to AIDS, as is a short incubation period (less
than 21 days between exposure and symptom
development), but most illnesses last less than 2 weeks.










THE NATURAL HISTORY OF
HN INFECTION
HIV produces a relentless, progressive and ultimately fa al
immunode'iciency syndrome in the vast majority of
infected umreated patients.
The immunodeficiency that develops during HIV infection
is a continuum, but the disease conveniently falls into
several discrete clinical phases. Adding the results of
simple blood tests to a clinical assessment allows the
treating clinician to make a remarkably accurate
assessment of the immediate risk of opportunistic disease,
and initiate preventive and antiviral therapy accordingly.
Understanding the natural history of HIV-infected people
allows a clinician to delay therapy when the risk of disease
is low, and initiate prevention and antiviral therapy when
that risk starts to rise.
Despite limited African prospective evidence, it seems that
the progression of immunodeficiency is very similar here to
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headaches and retro-orbital pain, mucocutaneous
inflammation and ulcers, lymphadenopathy, splenomegaly,
skin rashes, and gastrointestinal symptoms. The presence
of amorbilliform rash on the trunk is aclassic sign, but may
be less apparent in dark skins. Cases of opportunistic
diseases usually associated with advanced HIV have been
described, suggesting that immune damage during
seroconversion occurs. In a high HIV prevalence area such
as South Africa, any probable viral illness should warrant
questioning about risk factors, specifically possible recent
sexual exposure.
During seroconversion, virus-specific cellular immunity and
antibodies are generated in the face of a very high viral
load. Mucosal surfaces are protected by dendritic cells,
which efficiently transport the virus to lymphoid tissue
after sexual or other mucosal exposure. Within days of
exposure and infection of these Iymphocytes, viral
replication begins, and infected cells enter the bloodstream.
Massive amounts of virus, often numbering tens of millions
of copies, can be found in the bloodstream within a week
after infection, with seeding of lymphoid and other tissue.
The viral RNA and p24 levels are high, with a negative
enzyme-linked immunosorbent assay [ELlSA) and Western
blot, which become positive later. The host responds with
a strong cellular immune reaction, in an effort to contain
the virus, with full antibody response following, typically
within 21 to 28 days. Isolated incidences of seroconversion
up to a year later have been documented. Blood testing
during seroconversion will almost always show very high
viral loads. Low viral loads (less than 50 000 copies/ml)
with a negative ELlSA usually indicate a false positive viral
load. Viral load testing should therefore be interpreted
with care.
Clinical guidelines, including the Southern African
guidelines published in this edition, support the use of
antiretrovirals in the acute se;oconversion phase. These
recommendations are not yet backed by clinical trials
showing morbidity or mortality benefit, although some
work has shown significantly better CD4 rises in treated
patients immediately after seroconversion. The theory
around treating seroconversion illness is that the viral set
point (discussed later) may be set at a lower level, as the
body has less virus to fight during seroconversion,
prolonging the plateau phase. Treating aggressively with
antiretrovirals during this critical period may preserve key
HIV-specific T-helper cell responses. Enticing anecdotal
evidence exists of patients able to rely entirely on their own
immune system to control the virus, after a relatively brief
exposure to antiretrovirals during seroconversion, and
animal models suggest that treatment prolongs the plateau
phase. However, equally theoretical risks exist of the
archiving of drug-resistant virus, and there are the usual
concerns regarding toxicity with use of long-term
antiretrovirals. If one is to treat, it is not clear yet for how
long, at how high a viral load, or with which drugs. Many
experts recommend treating with conventional three-drug
regimens for a year, and then withdrawing, with close
monitoring subsequently. Clinical trials are currently
looking at this issue, but the results of these may be some
time away.
THE 'SET POINr
As HIV-specific cytotoxic T cells appear, the plasma viral
load drops dramatically. Neutralising antibodies only
appear after the viraemia has already started to decrease.
Resolution of symptoms usually corresponds with the drop
in viraemia.
The viral set point is established once the plasma viral load
has stopped falling. There is a large degree of individual
variation of the set point, but this tends to change fairly
slowly over the years following infection. People with high
set point viral loads tend to progress more rapidly to AIDS.
The set point appears to be associated with a large number
of interactive factors, including genetic differences in co-
receptors and qualitative differences in immune responses.
The HIV immune system model is one of an incompletely
effective antiviral immune response. The continued
interaction between host and virus may explain the
wasting syndrome seen in these patients - up to a billion
virions are released into the plasma and then subsequently
cleared by the immune system, every day, with loss of 5%
of the total CD4 population daily, creating a constant
regenerative stress.
Despite constan viral proliferation, and a persistent
immune reponse, HIV-infected people usually remain
asymptomatic during the time after seroconversion. During
this time the viral load remains relatively stable and the
CD4 count declines slowly, and the disease is often
mistakenly referred to as 'latent: Gradual destruction of
lymph node architecture occurs, and anergy to skin testing
develops. The onset of a more rapid drop of CD4 cells is
associated with accelerated disease, and is known as the
infiection point. The triggering events for this change in
viral and immune kinetics are poorly understood.
The CD4 cell count is widely used as a refiection of the
steady damage incurred by the immune system. There is
wide variability in the rate of decline of the CD4 count, with
some patients falling into 'fast' and 'slow' or even 'non'-
progressors, but the average time from seroconversion to
AIDS is about 10 years. CD4 cells are lost at an average of
40 - 80 cells/~1 per year. A high viral load predicts more
rapid progression. The progression rate is determined by a
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As the CD4 count approaches 200 cells/~I, the risk of
opportunistic disease rises dramatically. The spectrum of
disease changes steadily, and the presentation of other
diseases becomes more atypical. This sudden loss of
immune-virus homeostasis signifies an exhaustion of
Iymphocyte proliferative capacity, as well as possible
irreversible architectural damage to the lymph node
system.
LATE DISEASE
Fig. 2. Host-virus dynomics. The drap in CD4 during ocute
infection occurs in the foce of high viral loods; the ploteou
phose reflects viral-host homeostosis; finolly, immune contral
is lost, with 0 drap in CD4 count ond 0 rise in virallood.
The commoner HIV-related diseases in South Africa are
herpes zoster, oral candidiasis and tuberculosis. As the CD4
count drops, the clinical presentation of tuberculosis
changes, from the classic fibrocavitatory pulmonary
changes, to atypical lung changes including mediastinal
lymphadenopathy, and extrapulmonary TB. Responses to
treatment of opportunistic infections are also more
atypical, with incomplete responses, prolonged treatment
course requirements, and repeated relapses. With the CD4
count below 200 cells/~1 other common diseases start
becoming apparent, including cryptococcal meningitis,
pneumocystis, bacterial pneumonia, and oesophageal
candidiasis. Some diseases, such as cytomegalovirus and
non-tuberculous mycobacteria, appear to be less common
in our setting than in the developed world. These diseases,
in addition to other diseases such as progressive multifocal
leucoencephalopathy, radiculitis and central nervous
system lymphomas, are difficult and expensive to treat, and
are usually associated with a C04 count below 50 cells/~I,
with a very poor prognosis.
Set point
Effective prophylaxis against specific infections is available,
and is covered in the current guidelines, published in the
March of the Journol.
The term 'AIDS' is used to describe profound
immunosuppression, and is most commonly used in







Fig. 1. The troin-on-o-trock model The train is moving ot 0
certoin speed (virallood) olong 0 defined omount of trock (CD4
count!, towords disoster (AIDS).
The model often used is a 'train-on-a-track' heading for a
broken bridge (Fig. 1). The train represents the HIV-infected
person, and the broken bridge serious disease or death. The
length of track represents the CD4 count, and the speed of
the train the viral load. A person with a high CD4 (lots of
track) may still have a viral load that is high (the train is
travelling fast) and be expected to run into trouble sooner,
and therefore more frequent monitoring may be needed.
The analogy can be extended further - successful
antiretroviral therapy reduces the viral load (stops the
trainl, and allows the immune system and CD4 count to
recover (pushes the train backwards on the track).
During the 'plateau phase' HIV-positive persons are usually
asymptomatic, despite often having nonspecific laboratory
abnormalities. Mild cytopenia and raised liver
transaminase values are common. Occasionally patients
will have flares of immunological-related diseases,
particularly dermatological conditions, and have an
increased risk of drug idiosyncratic conditions. Persistent
generalised lymphadenopathy has no prognostic
significance.
As the disease progresses, headaches, night sweats,
anorexia, malaise and weight loss may occur, even in the
absence of opportunistic disease. Sinusitis is a common
and under-recognised syndrome. Mucocutaneous
manifestations and tuberculosis occur, even in the face of
relatively high CD4 counts, refiecting the limitations of this
surrogate measure of overall immune function. Plasma
CD4 counts refiect only 2010 of the total body's T-cell
population. The immune dysfunction is not simply a
quantitative loss of C04 and COB cells, but also of altered
diversity and strength of cellular immune response.
Hypergammaglobulinaemia is due to uncontrolled B-cell
replication, commonly seen as a raised total protein, and
auto-antibodies often test positive, despite the absence of
clinical manifestations associated with these antibodies.
Recurrent vaginal candidiasis is one of the commonest
early symptoms of HIV disease in women, often occurring
at CD4 counts of over 4D0 cells/~1.
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definitions, using CD4 counts and clinical criteria. Terms
like AIDS-related complex (ARC), referring to symptoms
pre-dating strict definitions of AIDS, have been abandoned.
All current treatment guidelines recommend starting
antiretrovirals if the CD4 count is found to be less than 200
cells/~1.
What is not clear is how soon before the '200 level'
antiretrovirals should be started, before the patient's risk
becomes great enough to warrant the cost, adherence and
toxicity challenges of lifelong antiretroviral treatment.
Most cohorts in the developed world show minimal disease
and minimal benefit of antiretrovirals above 350 cells/~l,
and the new guidelines specifically recommend not
starting antiretrovirals at this level unless the patient has
significant HIV-related symptoms or AIDS-related disease,
or is in the seroconversion phase. The Southern African
guidelines, along with other guidelines, recommend
stratifying the 200 - 350 cells/~1 into a high-risk group
(viral load greater than 55 000 copies), where treatment
should be started, versus a low-risk group (less than
55000), where closer monitoring is warranted.
CONCLUSION
The disease is predictable, and patients can be 'staged' into
broad risk categories according to clinical and
immunological criteria. These risk categories can be
correlated to the risk of disease progression, as well as
giving a good prediction of opportunistic illness risk. As
new, safer treatments and strategies or more accurate
predictors of risk become available, we may need to re-
evaluate the 'when-ta-start' criteria we use, especially as
the risk of tuberculosis increases even with relatively well
preserved CD4 counts. However, understanding the natural
history of the disease allows an accurate and sober
assessment of the individual patient's risk, with rational
initiation of treatment.
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